Go to
current issue
-
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, YuKyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
Journal of Clinical Oncology, Ahead of Print.
-
Restoration of Quality of Life and Functional Recovery After Colorectal Cancer Surgery in Older Adults J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Anthony Loria, Fergal J. Fleming
Journal of Clinical Oncology, Ahead of Print.
-
Improving Report of ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Danna Wu, Guo-Fu Li
Journal of Clinical Oncology, Ahead of Print.
-
Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Zachary R. McCaw, Paul G. Richardson, Lee-Jen Wei
Journal of Clinical Oncology, Ahead of Print.
-
Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Isacco Montroni, Giampaolo Ugolini, Nicole M. Saur, Siri Rostoft, Antonino Spinelli, Barbara L. Van Leeuwen, Nicola De Liguori Carino, Federico Ghignone, Michael T. Jaklitsch, Jakub Kenig, Anna Garutti, Chiara Zingaretti, Flavia Foca, Bernadette Vertogen, Oriana Nanni, Steven D. Wexner, Riccardo A. Audisio
Journal of Clinical Oncology, Ahead of Print.
-
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Michael L. Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S. Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar,
Journal of Clinical Oncology, Ahead of Print.
-
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Tanios S. Bekaii-Saab, Rona Yaeger, Alexander I. Spira, Meredith S. Pelster, Joshua K. Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hirak Der-Torossian, Shubham Pant
Journal of Clinical Oncology, Ahead of Print.
-
You Get (offered) What You (can) Pay for: Explaining Disparities in End-of-Life Cancer Care J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Holly G. Prigerson, Alfred I. Neugut
Journal of Clinical Oncology, Ahead of Print.
-
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Maureen Canavan, Xiaoliang Wang, Mustafa Ascha, Rebecca Miksad, Timothy N. Showalter, Gregory Calip, Cary P. Gross, Kerin Adelson
Journal of Clinical Oncology, Ahead of Print.
-
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Yiwen Ling, Li Xuan, Na Xu, Fen Huang, Zhiping Fan, Ziwen Guo, Xiaojun Xu, Hui Liu, Ren Lin, Sijian Yu, Haiyan Zhang, Hua Jin, Meiqing Wu, Can Liu, Xinquan Liang, Ruiming Ou, Yuping Zhang, Xiaodan Liu, Hong Qu, Xiao Zhai, Jing Sun, Ying Zhao, Qifa Liu
Journal of Clinical Oncology, Ahead of Print.
-
Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Reinhard Ruppert, Theodor Junginger, Rainer Kube, Joachim Strassburg, Andreas Lewin, Joerg Baral, Christoph A. Maurer, Joerg Sauer, Johannes Lauscher, Guenther Winde, Rena Thomasmeyer, Sigmar Stelzner, Cornelius Bambauer, Soenke Scheunemann, Axel Faedrich, Daniel Wollschlaeger, Susanne Merkel
Journal of Clinical Oncology, Ahead of Print.
-
Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Constantin Roder, Walter Stummer, Jan Coburger, Moritz Scherer, Patrick Haas, Christian von der Brelie, Marcel Alexander Kamp, Mario Löhr, Christina A. Hamisch, Marco Skardelly, Torben Scholz, Stephanie Schipmann, Julian Rathert, Catrin Marlene Brand, Andrej Pala, Ulrike Ernemann, Florian Stockhammer, Rüdiger Gerlach, Paul Kremer, Roland Goldbrunner, Ralf-Ingo Ernestus, Michael Sabel, Veit Rohde, Ghazaleh
Journal of Clinical Oncology, Ahead of Print.
-
Tradeoffs of Proceeding to Resection Rather Than Mediastinoscopy After Negative Endosonography J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Farhood Farjah
Journal of Clinical Oncology, Ahead of Print.
-
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Martin F. Kaiser, Andrew Hall, Katrina Walker, Amy Sherborne, Ruth M. De Tute, Nicola Newnham, Sadie Roberts, Emma Ingleson, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah R. Brown, Matthew W. Jenner
Journal of Clinical Oncology, Ahead of Print.
-
Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early-Onset Colorectal Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Eun Hyo Jin, Kyungdo Han, Cheol Min Shin, Dong Ho Lee, Seung Joo Kang, Joo Hyun Lim, Yoon Jin Choi
Journal of Clinical Oncology, Ahead of Print.
-
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Jeff M. Michalski, Kathryn A. Winter, Bradley R. Prestidge, Martin G. Sanda, Mahul Amin, William S. Bice, Hiram A. Gay, Geoffrey S. Ibbott, Juanita M. Crook, Charles N. Catton, Adam Raben, Walter Bosch, David C. Beyer, Steven J. Frank, Michael A. Papagikos, Seth A. Rosenthal, H. Joseph Barthold, Mack Roach, Jennifer Moughan, Howard M. Sandler
Journal of Clinical Oncology, Ahead of Print.
-
The CCDI Comes Out of the Starting Block J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Kevin Shannon
Journal of Clinical Oncology, Ahead of Print.
-
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Laura K. Hilton, Henry S. Ngu, Brett Collinge, Kostiantyn Dreval, Susana Ben-Neriah, Christopher K. Rushton, Jasper C.H. Wong, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Diego Villa, Judith A. Rodrigo, Kevin Song, Michael Crump, Lois Shepherd, Annette E. Hay, John Kuruvilla, Kerry J. Savage, Robert
Journal of Clinical Oncology, Ahead of Print.
-
Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Stéphanie Kermorgant
Journal of Clinical Oncology, Ahead of Print.
-
Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Hannah M. Seagle, Samantha R. Keller, Sean V. Tavtigian, Carolyn Horton, Andreana N. Holowatyj
Journal of Clinical Oncology, Ahead of Print.
-
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander Spira, Edward B. Garon, Satoru Kitazono, Melissa L. Johnson, Funda Meric-Bernstam, Anthony W. Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger-Gong, Fumiaki Kobayashi, Penny Phillips, Aaron E. Lisberg, Rebecca S. Heist
Journal of Clinical Oncology, Ahead of Print.
-
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C–Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Marcelo V. Negrao, Alexander I. Spira, Rebecca S. Heist, Pasi A. Jänne, Jose M. Pacheco, Jared Weiss, Shirish M. Gadgeel, Karen Velastegui, Wenjing Yang, Hirak Der-Torossian, James G. Christensen, Joshua K. Sabari
Journal of Clinical Oncology, Ahead of Print.
-
JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023
Journal of Clinical Oncology, Volume 41, Issue 18, Page 3277-3277, June 2023.
-
Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Andrew H. Ko
Journal of Clinical Oncology, Volume 41, Issue 18, Page 3275-3276, June 2023.
-
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
Journal of Clinical Oncology, Ahead of Print.
-
Encorafenib and Binimetinib: A New Treatment Option for BRAFV600E-Mutant Non–Small-Cell Lung Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Thomas E. Stinchcombe
Journal of Clinical Oncology, Ahead of Print.
-
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Ethan Basch, Amylou C. Dueck, Sandra A. Mitchell, Harvey Mamon, Martin Weiser, Leonard Saltz, Marc Gollub, Lauren Rogak, Brenda Ginos, Gina L. Mazza, Brian Colgrove, George Chang, Lori Minasian, Andrea Denicoff, Gita Thanarajasingam, Benjamin Musher, Thomas George, Alan Venook, Jeffrey Farma, Eileen O'Reilly, Jeffrey A. Meyerhardt, Qian Shi, Deborah Schrag
Journal of Clinical Oncology, Ahead of Print.
-
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd,
Journal of Clinical Oncology, Ahead of Print.
-
Use of Large Language Models and Artificial Intelligence Tools in Works Submitted to Journal of Clinical Oncology J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Kathy Miller, Emilie Gunn, Angela Cochran, Hal Burstein, Jonathan Friedberg, Stephanie Wheeler, Paul Frankel
Journal of Clinical Oncology, Ahead of Print.
-
Reply to M.C. Strach et al J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Michael B. Foote, Garrett M. Nash, Andrea Cercek
Journal of Clinical Oncology, Ahead of Print.
-
Genomic Subtypes of Appendiceal Adenocarcinoma: Enough to Guide Clinical Decision Making? J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Madeleine C. Strach, Kate Mahon, Jorge Barriuso
Journal of Clinical Oncology, Ahead of Print.
-
Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC. J. Clin. Oncol. (IF 45.3) Pub Date : 2023-05-01 Thomas E Stinchcombe
-
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Ian F. Tannock, Daniel A. Goldstein, Jonathan Ofer, Bishal Gyawali, Tomer Meirson
Journal of Clinical Oncology, Ahead of Print.
-
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J. Clin. Oncol. (IF 45.3) Pub Date : 2023-03-13 Siamak Daneshmand,Clint Cary,Timothy Masterson,Lawrence Einhorn,Nabil Adra,Stephen A Boorjian,Christian Kollmannsberger,Anne Schuckman,Alan So,Peter Black,Aditya Bagrodia,Eila Skinner,Mehrdad Alemozaffar,Timothy Brand,Scott Eggener,Phillip Pierorazio,Kelly Stratton,Lucia Nappi,Craig Nichols,Chunqiao Luo,Ming Li,Brian Hu
PURPOSE The long-term toxicities of chemotherapy and radiotherapy can represent a significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors with minimal late morbidity although little data exist on its efficacy in early metastatic seminoma. Surgery in early metastatic seminoma is a prospective phase II
-
DPYD Testing: Time to Put Patient Safety First J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Sharyn D. Baker, Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El-Deiry, William E. Evans, William D. Figg, Dan L. Hertz, J. Kevin Hicks, Suneel Kamath, Pashtoon Murtaza Kasi, Todd C. Knepper, Howard L. McLeod, Peter H. O'Donnell, Mary V. Relling, Michelle A. Rudek, Tristan M. Sissung, D. Max Smith, Alex Sparreboom, Sandra M. Swain, Christine M. Walko
Journal of Clinical Oncology, Ahead of Print.
-
Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Matthew P. Deek, Missak Haigentz, Salma K. Jabbour
Journal of Clinical Oncology, Ahead of Print.
-
Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Jessica Star, Priti Bandi, Rebecca L. Siegel, Xuesong Han, Adair Minihan, Robert A. Smith, Ahmedin Jemal
Journal of Clinical Oncology, Ahead of Print.
-
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Lissete Sánchez-Magraner, Juan Gumuzio, James Miles, Nicole Quimi, Purificación Martínez del Prado, María Teresa Abad-Villar, Fernando Pikabea, Laura Ortega, Carmen Etxezarraga, Salvador Martín-Algarra, María D. Lozano, Mónica Saiz-Camin, Mikel Egurrola-Izquierdo, Inmaculada Barredo-Santamaría, Alberto Saiz-López, Jenifer Gomez-Mediavilla, Nerea Segues-Merino, María Aranzazu Juaristi-Abaunz, Ander
Journal of Clinical Oncology, Ahead of Print.
-
The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer? J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Gerard A. Silvestri, James R. Jett
Journal of Clinical Oncology, Ahead of Print.
-
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, David Vicente, Julien Mazières, Jeronimo Rodríguez-Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew G. Robinson, Balazs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares
Journal of Clinical Oncology, Ahead of Print.
-
Impact of the COVID-19 Pandemic on Cancer Screening Delays J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Xiaochen Zhang, Mohamed I. Elsaid, Cecilia DeGraffinreid, Victoria L. Champion, Electra D. Paskett
Journal of Clinical Oncology, Ahead of Print.
-
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023 Xi Ding, Wei-Jing Zhang, Rui You, Xiong Zou, Zhi-Qiang Wang, Yan-Feng Ouyang, Lan Peng, You-Ping Liu, Chong-Yang Duan, Qi Yang, Chao Lin, Yu-Long Xie, Si-Yuan Chen, Yong-Long Liu, Chen-Mei Gu, Ruo-Qi Xie, Pei-Yu Huang, Ming-Huang Hong, Yi-Jun Hua, Ming-Yuan Chen
Journal of Clinical Oncology, Ahead of Print.
-
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) J. Clin. Oncol. (IF 45.3) Pub Date : 2022 Pamela L. Kunz, Noah T. Graham, Paul J. Catalano, Halla S. Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew E. Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane L. Reidy-Lagunes, Jonathan R. Strosberg, Peter J. O'Dwyer, Al B. Benson
Journal of Clinical Oncology, Ahead of Print.
-
FOxTROT: Are We Ready to Dance? J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-19 Julien Taieb, Mehdi Karoui
Colon cancer (CC) outcomes have improved significantly over the past two decades because of advances in the nonmetastatic setting. Since 2004 and the MOSAIC1 trial, infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; fluorouracil-leucovorin-oxaliplatin) for 6 months has been the standard adjuvant treatment for resected stage III patients and more controversially for high-risk stage II. More
-
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-19 Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Søren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray, on behalf of the FOxTROT Collaborative Group
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation.METHODS Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks postoperatively (control group)
-
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-17 Corey W. Speers, W. Fraser Symmans, William E. Barlow, Alex Trevarton, Stephanie The, Lili Du, James M. Rae, Steven Shak, Rick Baehner, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Daniel F. Hayes, Kathy S. Albain, Andrew Godwin, Alastair Thompson
PURPOSE Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2,3) index of endocrine-related transcription (SETER/PR) adjusted for baseline prognostic index
-
Risk of Major Psychiatric Disorders Among Children and Adolescents Surviving Malignancies: A Nationwide Longitudinal Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-17 Tien-Wei Hsu, Chih-Sung Liang, Shih-Jen Tsai, Ya-Mei Bai, Tung-Ping Su, Tzeng-Ji Chen, Mu-Hong Chen
PURPOSE Evidence suggests an increased long-term risk of major psychiatric disorders (MPDs) in childhood and adolescent cancer survivors (CACSs). However, definitive conclusions regarding such associations and whether such associations vary for different types of cancers remain unclear.METHODS Using a nationwide data set from 2001 to 2011, we enrolled CACSs and likewise randomly selected individuals
-
Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-17 Gary K. Schwartz
Journal of Clinical Oncology, Volume 41, Issue 3, Page 423-424, January 2023.
-
Trends in Anal Cancer: Leveraging Public Health Efforts to Improve Cancer Care J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-12 Alexandra Hotca, Karyn A. Goodman
Although anal cancer remains a rare disease, accounting for 0.5% of all new cancer cases,1 there has been a rise in incidence by up to 2.7% annually for the past decade in the United States.2 It is estimated that 9,440 individuals will be diagnosed with anal cancer in 2022, and up to 1,670 people will die of this disease.1 The rising incidence and mortality of squamous cell carcinoma of the anus (SCCA)
-
CAR T-Cells for Cure in Pediatric B-ALL J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-12 Rebecca A. Gardner, Nirali N. Shah
The first child to receive CD19 chimeric antigen receptor (CAR) T-cells has now been in a long-term remission—without interim therapy—for over a decade. This remission and early experience, followed by years of follow-up, served as a critical inflection point in pediatric B-cell acute lymphoblastic leukemia (B-ALL) therapy. Building on decades of collaborative efforts from pediatric oncologists worldwide
-
Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-12 Indra A. Van Assche, Evangeline A. Huis in 't Veld, Kristel Van Calsteren, Mathilde van Gerwen, Jeroen Blommaert, Elyce Cardonick, Michael J. Halaska, Robert Fruscio, Monica Fumagalli, Jurgen Lemiere, Elisabeth M. van Dijk-Lokkart, Camilla Fontana, Harm van Tinteren, Jessie De Ridder, Martine van Grotel, Marry M. van den Heuvel-Eibrink, Lieven Lagae, Frédéric Amant
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already
-
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-12 Peter G. Mikhael, Jeremy Wohlwend, Adam Yala, Ludvig Karstens, Justin Xiang, Angelo K. Takigami, Patrick P. Bourgouin, PuiYee Chan, Sofiane Mrah, Wael Amayri, Yu-Hsiang Juan, Cheng-Ta Yang, Yung-Liang Wan, Gigin Lin, Lecia V. Sequist, Florian J. Fintelmann, Regina Barzilay
PURPOSE Low-dose computed tomography (LDCT) for lung cancer screening is effective, although most eligible people are not being screened. Tools that provide personalized future cancer risk assessment could focus approaches toward those most likely to benefit. We hypothesized that a deep learning model assessing the entire volumetric LDCT data could be built to predict individual risk without requiring
-
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-10 Beverly Moy, R. Bryan Rumble, Lisa A. Carey, for the Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Expert Panel
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner
-
Reply to S. Al Hadidi et al J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-10 Meletios A. Dimopoulos, Jesús San-Miguel
Our final overall survival (OS) analysis from the randomized phase II ELOQUENT–3 trial demonstrated that elotuzumab combined with pomalidomide/dexamethasone (EPd) resulted in a statistically significant improvement in OS versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (MM) who received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor
-
Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-10 Ang Li, Jennifer La, Sarah B. May, Danielle Guffey, Wilson L. da Costa Jr, Christopher I. Amos, Raka Bandyo, Emily M. Milner, Karen M. Kurian, Daniel C.R. Chen, Nhan V. Do, Carolina Granada, Nimrah Riaz, Mary T. Brophy, Vipul Chitalia, J. Michael Gaziano, David A. Garcia, Marc Carrier, Christopher R. Flowers, Neil A. Zakai, Nathanael R. Fillmore
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy.METHODS Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage
-
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-10 Victoria A. Sanchez, Megan M. Shuey, Paul C. Dinh Jr, Patrick O. Monahan, Sophie D. Fosså, Howard D. Sesso, M. Eileen Dolan, Lawrence H. Einhorn, David J. Vaughn, Neil E. Martin, Darren R. Feldman, Kurt Kroenke, Chunkit Fung, Robert D. Frisina, Lois B. Travis
PURPOSE Cisplatin is widely used and highly ototoxic, but patient-reported functional impairment because of cisplatin-related hearing loss (HL) and tinnitus has not been comprehensively evaluated.PATIENTS AND METHODS Testicular cancer survivors (TCS) given first-line cisplatin-based chemotherapy completed validated questionnaires, including the Hearing Handicap Inventory for Adults (HHIA) and Tinnitus
-
Racial and Ethnic Disparities in Opioid Access and Urine Drug Screening Among Older Patients With Poor-Prognosis Cancer Near the End of Life J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-10 Andrea C. Enzinger, Kaushik Ghosh, Nancy L. Keating, David M. Cutler, Cheryl R. Clark, Narjust Florez, Mary Beth Landrum, Alexi A. Wright
PURPOSE To characterize racial and ethnic disparities and trends in opioid access and urine drug screening (UDS) among patients dying of cancer, and to explore potential mechanisms.METHODS Among 318,549 non-Hispanic White (White), Black, and Hispanic Medicare decedents older than 65 years with poor-prognosis cancers, we examined 2007-2019 trends in opioid prescription fills and potency (morphine milligram
-
Vaccines Targeting Gliomas: Antigens Matter J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-09 Michael Platten, Niklas Grassl
Journal of Clinical Oncology, Ahead of Print.
-
Immunotherapy in Localized Microsatellite Instability–High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-09 Kristen K. Ciombor, Cathy Eng
The hallmark of mismatch repair deficiency is the inability to repair spontaneous mutations during DNA replication, resulting in high tumor mutational burden levels and altered DNA microsatellite sequences or microsatellite instability (MSI).1-3 Although initially this feature was identified as a preliminary screening test for hereditary cancer syndromes such as Lynch syndrome,4 mismatch repair deficiency
-
Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non–Small-Cell Lung Cancer? J. Clin. Oncol. (IF 45.3) Pub Date : 2023-01-09 Ziming Li, Shun Lu
The standard of care for the first-line treatment of advanced non–small-cell lung cancer (NSCLC) without targetable mutations has recently shifted from chemotherapy to immunotherapy-based regimens; in current clinical practice, immunotherapy with or without chemotherapy is generally determined by the level of programmed death ligand 1 (PD-L1) expression on the tumor. Clinically, there are multiple
更新日期：2023-07-03
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号